3.1 The LEADER Trial The LEADER trial was a double-blind, randomized, placebo-controlled study designed to evaluate the cardiovascular safety of liraglutide in 9340 patients with T2DM and high cardiovascular risk
These components produce the tear films three layers: lipid, aqueous, and mucin, which are crucial for ocular lubrication and protection (The definition, 2007
The exclusion criteria were: severe or chronic skin inflammation, serious inner or chronic diseases, intake of drugs that can possibly interfere with skin reactions, application of pharmaceutical or skin care products with active ingredients until 10 days before testing, allergies or severe side effects after usage of cosmetic products, sunbath or usage of tanning bed during the study period, known cancer, pregnancy or lactation period, taking of medication with potential effect on hair growth
What should patients consider when choosing between Tirzepatide and Semaglutide for weight loss
250 mg/d), GSH (Setria
Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis
